JP2014530597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530597A5 JP2014530597A5 JP2014530333A JP2014530333A JP2014530597A5 JP 2014530597 A5 JP2014530597 A5 JP 2014530597A5 JP 2014530333 A JP2014530333 A JP 2014530333A JP 2014530333 A JP2014530333 A JP 2014530333A JP 2014530597 A5 JP2014530597 A5 JP 2014530597A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- item
- isolated
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 103
- 150000001875 compounds Chemical class 0.000 claims description 49
- 239000003112 inhibitor Substances 0.000 claims description 40
- 208000034799 Tauopathies Diseases 0.000 claims description 34
- 208000024827 Alzheimer disease Diseases 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 24
- 230000001575 pathological effect Effects 0.000 claims description 22
- 230000002776 aggregation Effects 0.000 claims description 19
- 238000004220 aggregation Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 9
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 9
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 9
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 239000003524 antilipemic agent Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 9
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 229910052723 transition metal Inorganic materials 0.000 claims description 9
- 150000003624 transition metals Chemical class 0.000 claims description 9
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 8
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 8
- 238000007913 intrathecal administration Methods 0.000 claims description 7
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 241001260012 Bursa Species 0.000 claims description 4
- 108700012434 CCL3 Proteins 0.000 claims description 4
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 4
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000009843 Thyroglobulin Human genes 0.000 claims description 4
- 108010034949 Thyroglobulin Proteins 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000007914 intraventricular administration Methods 0.000 claims description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 4
- 239000005022 packaging material Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 229960002175 thyroglobulin Drugs 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000002967 competitive immunoassay Methods 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 231100000915 pathological change Toxicity 0.000 claims 1
- 230000036285 pathological change Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 description 87
- 108010026424 tau Proteins Proteins 0.000 description 87
- 108090000765 processed proteins & peptides Proteins 0.000 description 66
- 239000002671 adjuvant Substances 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940016590 sarkosyl Drugs 0.000 description 4
- 108700004121 sarkosyl Proteins 0.000 description 4
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 229940122777 Tau aggregation inhibitor Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- -1 phospho group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229940121773 Secretase inhibitor Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536339P | 2011-09-19 | 2011-09-19 | |
| US61/536,339 | 2011-09-19 | ||
| US201261653115P | 2012-05-30 | 2012-05-30 | |
| US61/653,115 | 2012-05-30 | ||
| PCT/IB2012/002246 WO2013041962A1 (en) | 2011-09-19 | 2012-09-14 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230258A Division JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530597A JP2014530597A (ja) | 2014-11-20 |
| JP2014530597A5 true JP2014530597A5 (https=) | 2015-11-05 |
| JP6253583B2 JP6253583B2 (ja) | 2017-12-27 |
Family
ID=47216372
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530333A Active JP6253583B2 (ja) | 2011-09-19 | 2012-09-14 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2016230258A Active JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230258A Active JP6360869B2 (ja) | 2011-09-19 | 2016-11-28 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2017033138A Active JP6286590B2 (ja) | 2011-09-19 | 2017-02-24 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018059946A Active JP6499345B2 (ja) | 2011-09-19 | 2018-03-27 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2018132100A Active JP6637124B2 (ja) | 2011-09-19 | 2018-07-12 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2019228943A Active JP6950981B2 (ja) | 2011-09-19 | 2019-12-19 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
| JP2021150176A Active JP7182316B2 (ja) | 2011-09-19 | 2021-09-15 | アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9518101B2 (https=) |
| EP (2) | EP3275461A1 (https=) |
| JP (7) | JP6253583B2 (https=) |
| KR (3) | KR102130439B1 (https=) |
| CN (3) | CN109265543B (https=) |
| AU (3) | AU2012311234B2 (https=) |
| BR (1) | BR112014006376B1 (https=) |
| CA (1) | CA2848346A1 (https=) |
| CL (3) | CL2014000679A1 (https=) |
| CY (1) | CY1119792T1 (https=) |
| DK (1) | DK2758433T3 (https=) |
| ES (1) | ES2656442T3 (https=) |
| HR (1) | HRP20180083T8 (https=) |
| HU (1) | HUE036177T2 (https=) |
| IL (4) | IL231201B (https=) |
| LT (1) | LT2758433T (https=) |
| ME (1) | ME03008B (https=) |
| MX (2) | MX391157B (https=) |
| MY (1) | MY183989A (https=) |
| PL (1) | PL2758433T3 (https=) |
| PT (1) | PT2758433T (https=) |
| RS (1) | RS56852B1 (https=) |
| RU (2) | RU2018102103A (https=) |
| SG (4) | SG10201703771WA (https=) |
| SI (1) | SI2758433T1 (https=) |
| SM (1) | SMT201800109T1 (https=) |
| TR (1) | TR201800669T4 (https=) |
| UA (2) | UA123390C2 (https=) |
| WO (1) | WO2013041962A1 (https=) |
| ZA (1) | ZA201401333B (https=) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703137B2 (en) * | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| ES2656442T3 (es) * | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| HK1209768A1 (en) | 2012-07-03 | 2016-04-08 | Washington University | Antibodies to tau |
| PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3074420A2 (en) * | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6654899B2 (ja) * | 2013-12-26 | 2020-02-26 | 東亞合成株式会社 | カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド |
| WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| WO2015197820A1 (en) * | 2014-06-26 | 2015-12-30 | Crucell Holland B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| SI3221349T1 (sl) * | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
| AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP4465050A3 (en) | 2015-06-05 | 2025-06-11 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| KR102770650B1 (ko) * | 2015-07-06 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | 타우 결합 항체 |
| CA2991264C (en) | 2015-07-06 | 2023-10-10 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201518675D0 (en) * | 2015-10-21 | 2015-12-02 | Cellcap Technologies Ltd | Detection of structural forms of proteins |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3022515A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| KR101997319B1 (ko) * | 2016-06-21 | 2019-07-08 | 전남대학교산학협력단 | 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용 |
| EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| MA48595A (fr) | 2016-12-07 | 2020-03-18 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
| CN117820467A (zh) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11001615B2 (en) | 2016-12-21 | 2021-05-11 | Adel Inc. | Mutated tau protein fragment and use thereof |
| BR112019017021A2 (pt) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| WO2018178077A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| WO2018195376A1 (en) * | 2017-04-21 | 2018-10-25 | Ohio University | Peptide-based inhibitors of mark family proteins |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP7029718B2 (ja) * | 2017-07-31 | 2022-03-04 | 国立研究開発法人量子科学技術研究開発機構 | リン酸化タウタンパク質の測定方法 |
| JP6979533B2 (ja) | 2017-10-02 | 2021-12-15 | ブラックソーン セラピューティクス インコーポレイテッド | 対象における神経行動学的表現型を検知、診断、予測、予知、または処置するための方法及びツール |
| EP3697814A1 (en) * | 2017-10-16 | 2020-08-26 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| KR102710762B1 (ko) | 2017-10-25 | 2024-09-25 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| CA3079236A1 (en) * | 2017-10-27 | 2019-05-02 | United Neuroscience | Tau peptide immunogen constructs |
| WO2019120527A1 (en) * | 2017-12-20 | 2019-06-27 | Michael Heneka | Novel means and methods for treating neurodegenerative diseases |
| CN111918875A (zh) | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
| WO2019186276A2 (en) * | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
| RU2679059C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| RU2679080C1 (ru) * | 2018-04-17 | 2019-02-05 | Александр Олегович Морозов | Пептид и способ лечения болезни альцгеймера |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| WO2019213612A1 (en) * | 2018-05-03 | 2019-11-07 | Washington University | Methods of diagnosing and treating based on site-specific tau phosphorylation |
| SG11202012759XA (en) | 2018-07-03 | 2021-01-28 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| US20220273779A1 (en) * | 2018-11-19 | 2022-09-01 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
| CN113166235A (zh) * | 2018-11-22 | 2021-07-23 | 富士瑞必欧株式会社 | 抗体偶联物 |
| WO2020120644A1 (en) * | 2018-12-13 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| AU2020219804A1 (en) | 2019-02-08 | 2021-08-19 | Ac Immune S.A. | Method of safe administration of phosphorylated Tau peptide vaccine |
| WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN113631573B (zh) * | 2019-03-25 | 2024-06-04 | 国家医疗保健研究所 | 抗Tau抗体及其在制备用于治疗疾病的药物中的用途 |
| EA202192891A1 (ru) * | 2019-04-24 | 2022-02-04 | Янссен Фармасьютикалз, Инк. | Гетерологичное введение анти-тау вакцин |
| MX2021014473A (es) * | 2019-05-31 | 2022-01-06 | Lilly Co Eli | Compuestos y metodos dirigidos a la tau humana. |
| GB201909393D0 (en) * | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| MX2022001817A (es) * | 2019-08-13 | 2022-03-11 | Washington University St Louis | Metodos para detectar isoformas de la region de union a microtubulos (mtbr) tau y uso de las mismas. |
| CN114531877B (zh) * | 2019-08-15 | 2024-11-15 | 学校法人东京医科大学 | 不受clsp阻碍物质影响的clsp衍生物和clsp活性的增强/保护剂 |
| EP4028040A2 (en) | 2019-09-09 | 2022-07-20 | Axon Neuroscience SE | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| EP4028775A4 (en) | 2019-09-10 | 2023-04-12 | Washington University | BLOOD-BASED TEST FOR DIAGNOSIS AND TREATMENT BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION |
| MX2022004678A (es) * | 2019-10-22 | 2022-08-15 | Biogen Ma Inc | Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. |
| IL270800A (en) * | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
| CN110841059A (zh) * | 2019-12-03 | 2020-02-28 | 南通大学 | 老年性痴呆小鼠模型的制备方法 |
| WO2021157634A1 (ja) * | 2020-02-05 | 2021-08-12 | 大日本住友製薬株式会社 | タウオパチーおよび認知症関連疾患の判定薬および判定方法 |
| WO2021236809A2 (en) * | 2020-05-19 | 2021-11-25 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| KR20230080397A (ko) * | 2020-08-07 | 2023-06-07 | 오타이르 프로테나 리미티드 | 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신 |
| AU2021321206A1 (en) * | 2020-08-07 | 2023-03-09 | Othair Prothena Limited | Tau vaccine for the treatment of alzheimer's disease |
| JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス，インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
| US20240066146A1 (en) * | 2020-12-18 | 2024-02-29 | Sangamo Therapeutics, Inc. | Improved pharmaceutical compositions containing adeno-associated viral vector |
| IL305161A (en) * | 2021-02-14 | 2023-10-01 | Prothena Biosciences Ltd | Methods of using TAU detection antibodies |
| WO2022176959A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| EP4297868A4 (en) | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | USE OF APREPITANT TO TREAT ALZHEIMER'S |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| CN113430230A (zh) * | 2021-06-24 | 2021-09-24 | 南通大学 | tau截断体蛋白在诱导tau病理聚集中的应用 |
| EP4115976B1 (en) * | 2021-07-05 | 2026-04-29 | Alois Data GmbH | Reaction vessel |
| EP4413366A4 (en) * | 2021-10-08 | 2025-09-10 | Tiberias Tech Hk Limited | TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17 |
| CN113861441A (zh) * | 2021-10-28 | 2021-12-31 | 南开大学 | 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN116554342A (zh) * | 2022-01-29 | 2023-08-08 | 元本(珠海横琴)生物科技有限公司 | 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株 |
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | TAU PROTEIN BINDING COMPOUNDS |
| WO2025019332A1 (en) * | 2023-07-14 | 2025-01-23 | Alzpath, Inc. | Methods for remote blood collection, extraction and analysis of neuro biomarkers |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
| CN117624354B (zh) * | 2023-11-30 | 2024-07-12 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau281兔单克隆抗体及其应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| ATE398176T1 (de) * | 1991-12-06 | 2008-07-15 | Max Planck Gesellschaft | Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| AU705889B2 (en) | 1993-08-26 | 1999-06-03 | Regents Of The University Of California, The | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| EP0791067B1 (en) * | 1994-10-28 | 2008-12-17 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Protein kinase npk-110 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5643207A (en) | 1995-04-28 | 1997-07-01 | Medtronic, Inc. | Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| NZ322175A (en) | 1995-11-10 | 1999-02-25 | Elan Corp Plc | Peptides which enhance transport across tissues and methods of identifying the same |
| US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US6198966B1 (en) | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
| JP3383618B2 (ja) | 1999-08-18 | 2003-03-04 | 松下電器産業株式会社 | 移動体通信端末装置及び受信強度検出方法 |
| WO2001018544A1 (en) * | 1999-09-09 | 2001-03-15 | Mcgill University | Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases |
| AU7653100A (en) | 1999-09-09 | 2001-04-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | A minimal tau peptide for the nucleation of paired helical filaments |
| US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| ES2276732T3 (es) | 2001-09-03 | 2007-07-01 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Mimotopos de antigenos y vacuna contra enfermedades cancerosas. |
| TWI226905B (en) | 2001-10-19 | 2005-01-21 | Bioware Technology Co Ltd | Low pressure-accelerated particle gene gun |
| CN100572392C (zh) | 2002-07-12 | 2009-12-23 | 阿克松神经科学研究和发展股份有限公司 | 截短tau蛋白 |
| CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| US7521230B2 (en) * | 2002-10-16 | 2009-04-21 | Board Of Regents Of The University Of Nebraska | Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof |
| EP1516930A1 (en) | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| WO2005035721A2 (en) | 2003-10-08 | 2005-04-21 | Ebioscience | Native immunoglobulin binding reagents and methods for making and using same |
| CN1721437A (zh) * | 2004-07-13 | 2006-01-18 | 中南大学 | 一种与Tau蛋白相关的多肽抗原及抗体 |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| ATE524487T1 (de) | 2007-01-11 | 2011-09-15 | Univ Ramot | Tau peptidmimetikum zur behandlung von neurodegenerativen erkrankungen |
| EP2149584B1 (en) * | 2007-04-20 | 2017-12-13 | The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
| WO2009000520A1 (en) | 2007-06-25 | 2008-12-31 | Universität Duisburg-Essen | Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| EP2470211B1 (en) | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
| WO2011053565A2 (en) * | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| DK2496594T3 (en) | 2009-11-06 | 2018-03-05 | The J David Gladstone Inst | METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS |
| IN2012DN05145A (https=) * | 2009-11-19 | 2015-10-23 | Solis Biodyne | |
| CL2010000019A1 (es) | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
| ES2656442T3 (es) * | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2012
- 2012-09-14 ES ES12788639.8T patent/ES2656442T3/es active Active
- 2012-09-14 SG SG10201703771WA patent/SG10201703771WA/en unknown
- 2012-09-14 LT LTEP12788639.8T patent/LT2758433T/lt unknown
- 2012-09-14 PL PL12788639T patent/PL2758433T3/pl unknown
- 2012-09-14 JP JP2014530333A patent/JP6253583B2/ja active Active
- 2012-09-14 ME MEP-2018-18A patent/ME03008B/me unknown
- 2012-09-14 HU HUE12788639A patent/HUE036177T2/hu unknown
- 2012-09-14 KR KR1020147010525A patent/KR102130439B1/ko active Active
- 2012-09-14 WO PCT/IB2012/002246 patent/WO2013041962A1/en not_active Ceased
- 2012-09-14 CN CN201810662577.7A patent/CN109265543B/zh active Active
- 2012-09-14 DK DK12788639.8T patent/DK2758433T3/en active
- 2012-09-14 BR BR112014006376-1A patent/BR112014006376B1/pt active IP Right Grant
- 2012-09-14 RU RU2018102103A patent/RU2018102103A/ru unknown
- 2012-09-14 HR HRP20180083TT patent/HRP20180083T8/hr unknown
- 2012-09-14 SG SG10201912955PA patent/SG10201912955PA/en unknown
- 2012-09-14 RS RS20180054A patent/RS56852B1/sr unknown
- 2012-09-14 EP EP17190247.1A patent/EP3275461A1/en active Pending
- 2012-09-14 MY MYPI2014000803A patent/MY183989A/en unknown
- 2012-09-14 CA CA2848346A patent/CA2848346A1/en not_active Abandoned
- 2012-09-14 MX MX2017005573A patent/MX391157B/es unknown
- 2012-09-14 UA UAA201706478A patent/UA123390C2/uk unknown
- 2012-09-14 CN CN201280056856.XA patent/CN104185640B/zh active Active
- 2012-09-14 SI SI201231187T patent/SI2758433T1/en unknown
- 2012-09-14 AU AU2012311234A patent/AU2012311234B2/en active Active
- 2012-09-14 EP EP12788639.8A patent/EP2758433B1/en active Active
- 2012-09-14 UA UAA201404170A patent/UA115657C2/uk unknown
- 2012-09-14 SG SG11201400125RA patent/SG11201400125RA/en unknown
- 2012-09-14 KR KR1020207018712A patent/KR102285743B1/ko active Active
- 2012-09-14 SM SM20180109T patent/SMT201800109T1/it unknown
- 2012-09-14 US US14/345,561 patent/US9518101B2/en active Active
- 2012-09-14 RU RU2014115481A patent/RU2645259C2/ru active
- 2012-09-14 PT PT127886398T patent/PT2758433T/pt unknown
- 2012-09-14 CN CN202210373330.XA patent/CN115417916B/zh active Active
- 2012-09-14 TR TR2018/00669T patent/TR201800669T4/tr unknown
- 2012-09-14 SG SG10201912964PA patent/SG10201912964PA/en unknown
- 2012-09-14 KR KR1020217024024A patent/KR20210099167A/ko not_active Ceased
- 2012-09-14 MX MX2014003357A patent/MX347505B/es active IP Right Grant
-
2014
- 2014-02-21 ZA ZA2014/01333A patent/ZA201401333B/en unknown
- 2014-02-27 IL IL231201A patent/IL231201B/en active IP Right Grant
- 2014-03-19 CL CL2014000679A patent/CL2014000679A1/es unknown
-
2015
- 2015-05-14 CL CL2015001314A patent/CL2015001314A1/es unknown
-
2016
- 2016-01-27 CL CL2016000215A patent/CL2016000215A1/es unknown
- 2016-11-03 US US15/342,629 patent/US9828421B2/en active Active
- 2016-11-28 JP JP2016230258A patent/JP6360869B2/ja active Active
-
2017
- 2017-02-24 JP JP2017033138A patent/JP6286590B2/ja active Active
- 2017-05-19 US US15/599,685 patent/US9845352B2/en active Active
- 2017-11-02 US US15/801,341 patent/US11098106B2/en active Active
- 2017-12-07 AU AU2017272259A patent/AU2017272259B2/en active Active
-
2018
- 2018-01-17 CY CY20181100058T patent/CY1119792T1/el unknown
- 2018-03-27 JP JP2018059946A patent/JP6499345B2/ja active Active
- 2018-06-03 IL IL259775A patent/IL259775B/en active IP Right Grant
- 2018-07-12 JP JP2018132100A patent/JP6637124B2/ja active Active
-
2019
- 2019-12-19 JP JP2019228943A patent/JP6950981B2/ja active Active
-
2020
- 2020-01-29 AU AU2020200624A patent/AU2020200624B2/en active Active
- 2020-05-04 IL IL274440A patent/IL274440B/en unknown
-
2021
- 2021-07-27 US US17/443,779 patent/US12404322B2/en active Active
- 2021-09-15 JP JP2021150176A patent/JP7182316B2/ja active Active
- 2021-11-02 IL IL287794A patent/IL287794A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530597A5 (https=) | ||
| JP7532571B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| RU2014115481A (ru) | Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера | |
| US12145988B2 (en) | Anti-TREM-2 agonist antibodies | |
| EP3534937B1 (en) | Antibodies to pyroglutamate amyloid-beta and uses thereof | |
| US8323651B2 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| CA3007000C (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| CN105283196B (zh) | 用于产生和使用构象-特异性抗体的方法和组合物 | |
| JP2022058369A (ja) | アルツハイマー病治療方法 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| US20160002343A1 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| AU2009303453B2 (en) | Use of IGF-II/IGF-IIE binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis | |
| KR20250150001A (ko) | 항-Aβ 항체를 이용한 신경계 장애의 치료 방법 | |
| HK1178913A (en) | ANTI-Aβ ANTIBODIES AND THEIR USE |